Apeloa Pharmaceutical recently participated in three major industry events—ChemOutsourcing and BioPacific in the United States and Nordic Life Science Days (NLS Days) in Europe. Through this multi-regional, multi-platform presence, the company highlighted its CDMO technology platforms, manufacturing capacity, and compliance capabilities, while engaging with pharmaceutical companies and innovative teams across North America and Europe.
The events were part of Apeloa’s broader effort to connect with global pharmaceutical innovation resources and steadily advance its global CDMO strategy. Leveraging its three major CDMO R&D centers in Boston, Shanghai Pudong, and Hengdian, Zhejiang, Apeloa provides global innovative drug customers with one-stop services from process development, scale-up, to commercial manufacturing. This intergrated network further strengthens the company’s international service capabilities through the synergy of technology, network, and talent.
Expanding Presence in North America’s Innovation Hub
North America is a core hub for global biomedical innovation, home to leading pharmaceutical companies and emerging biotech startups. ChemOutsourcing and BioPacific are among the region’s most influential industry events. Apeloa’s North American participation was led by George Cai, Senior Vice President, and General Manager of CDMO Business Unit, together with the company’s BD team. The team showcased Apeloa’s full-chain CDMO R&D and production services, as well as its distinctive technology platforms, including green synthesis, continuous flow chemistry, and biocatalysis, along with their industrial applications.
At the Lunch & Learn session at BioPacific, Victor Li, Vice President of CDMO Business Unit, delivered a presentation. He noted that as innovative drug R&D becomes more challenging and molecular complexity increases, pharmaceutical companies are seeking CDMO partners that offer not only contract manufacturing but also stronger scientific rigor, agility, and reliability in CMC collaboration. Relying on its integrated R&D network across Boston, Shanghai, and Hengdian and its European office, Apeloa’s CDMO business has built an end-to-end service system covering Flow Chemistry, Peptides, ADCs, PROTACs, and other modalities. With capabilities centered on rapid response, reliable compliance, and cost efficiency, Apeloa helps global customers advance the industrialization of innovative drugs.
During the events, Apeloa’s team held one-on-one discussion with a number of North American pharmaceutical and biotech companies on process development, capacity support, project advancement, and long-term cooperation. The company’s mature technology platforms, comprehensive global compliance system, and stable production capacity drew strong interest from participating companies and led to several preliminary cooperation opportunities, further expanding its presence in the North American innovative drug market.
Strengthening CDMO Competitiveness in Europe’s Core Market
NLS Days is an influential professional event in Europe’s biomedical sector, focusing on CMC processes for innovative drugs, supply chain optimization, and industry compliance. It brings together Nordic and European pharmaceutical companies, R&D institutions, and industry chain service providers, serving as an efficient platform for technical exchange and business matchmaking.
Notably, this was Apeloa’s first independent exhibition at NLS Days. As a member of Medicon Valley Alliance (MVA), a cross-border Danish-Swedish life science cluster, Apeloa has long been active in the European market and has established a stable customer base and local service resources. At NLS Days, the company further leveraged the MVA platform to strengthen exchanges with key players in Nordic and European biomedicine and enhance its service capabilities in the European market.
In recent years, Apeloa has continued to expand its European market presence. The company has established a wholly owned subsidiary, APELOA EUROPE GmbH, in Frankfurt, Germany, and appointed Dr. Michael Stanek as Senior Vice President of the CDMO Business Unit and General Manager of APELOA EUROPE GmbH. Dr. Stanek oversees European operations, global CDMO business development, and cross border team and supply chain management, further strengthening Apeloa’s localized operations in Europe and enhancing its global competitiveness in CDMO services.
Apeloa showcases at three major U.S. and European events reflects the company’s commitment to its internationalization strategy and its efforts to enhance global CDMO service capabilities. Looking ahead, Apeloa will continue to strengthen its technology platforms, manufacturing capacity, compliance capabilities, and global response capabilities. The company will deepen its presence in core overseas markets such as North America and Europe, supporting the efficient industrialization of global innovative drugs with high-quality, reliable, and trustworthy CDMO services, while further driving its international growth.
